Summary:
The investigational drug, JZP150, is currently being tested and so its use in posttraumatic stress disorder is experimental. It has not been approved by the FDA (US Food and Drug Administration), the health authority that gives approval for new drugs to be prescribed in the United States.
Qualified Participants Must:
Be aged 18 to 70 years
A primary diagnosis of PTSD
Capable of giving signed informed consent
A traumatic event occurring within the last 12 years
Qualified Participants May Receive:
Compensation for time and travel upon meeting study qualifications